A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Parkinson Disease
Interventions
PROCEDURE

[123I]β-CIT and SPECT imaging

This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.

DRUG

[123I]β-CIT

SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Molecular NeuroImaging

OTHER

lead

Institute for Neurodegenerative Disorders

OTHER